EGFR and neoplasm: Furthermore, emerging research indicates that the addition of immunotherapy agents, such as nivolumab targeting the programmed death-ligand 1 (PD-L1) pathway, or target therapy agents, epidermal growth factor receptor (EGFR) inhibitors like cetuximab, with conventional cisplatin-based chemotherapy enhances tumor response rates without increasing overall treatment-related toxicity [10].